These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1490510)

  • 1. DNA flow cytometry and neo-adjuvant chemotherapy/radiotherapy in operable muscle-invasive bladder carcinoma. A preliminary report.
    Jacobsen AB; Berner A; Juul M; Ous S; Pettersen EO; Fosså SD
    Eur Urol; 1992; 22(4):316-22. PubMed ID: 1490510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA ploidy and S-phase fraction as predictive factors of response and outcome following neoadjuvant methotrexate, vinblastine, epirubicin and cisplatin (M-VEC) chemotherapy for invasive bladder cancer.
    Türkölmez K; Baltaci S; Bedük Y; Müftüoğlu YZ; Göğüş O
    Scand J Urol Nephrol; 2002 Feb; 36(1):46-51. PubMed ID: 12002357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of DNA ploidy in bladder cancer treated with preoperative radiation therapy and cystectomy.
    Granfors T; Duchek M; Tomic R; Roos G; Ljungberg B
    Scand J Urol Nephrol; 1996 Aug; 30(4):281-5. PubMed ID: 8908649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of DNA ploidy and S-phase fraction and their relation to p53 protein, c-erbB-2 protein and HCG in operable muscle-invasive bladder cancer.
    Fosså SD; Berner AA; Jacobsen AB; Waehre H; Kvarstein B; Urnes T; Ogreid P; Johansen TE; Silde J; Nesland JM
    Br J Cancer; 1993 Sep; 68(3):572-8. PubMed ID: 8102536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA ploidy as a prognostic factor in muscle invasive transitional cell carcinoma of the bladder.
    Deliveliotis C; Georgoulakis J; Skolarikos A; Trakas N; Varkarakis J; Albanis S; Protogerou B; Bamias A
    Urol Res; 2005 Feb; 33(1):39-43. PubMed ID: 15258707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deoxyribonucleic acid flow cytometry in invasive bladder carcinoma: a possible predictor for successful bladder preservation following transurethral surgery and chemotherapy-radiotherapy.
    Hug EB; Donnelly SM; Shipley WU; Heney NM; Kaufman DS; Preffer FI; Schwartz SM; Colvin RB; Althausen AF
    J Urol; 1992 Jul; 148(1):47-51. PubMed ID: 1613879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deoxyribonucleic acid ploidy and the clinical pattern of grade 2 superficial bladder cancer.
    Neulander E; Kaneti J; Chaimovitz C; Sion-Vardy N; Douvdevani A
    J Urol; 1997 Apr; 157(4):1254-8; discussion 1258-9. PubMed ID: 9120914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic significance of deoxyribonucleic acid flow cytometry in muscle invasive bladder carcinoma treated with preoperative irradiation and cystectomy.
    Jacobsen AB; Pettersen EO; Amellem O; Berner A; Ous S; Fosså SD
    J Urol; 1992 Jan; 147(1):34-7. PubMed ID: 1729547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
    Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nm23-H1 protein, DNA-ploidy and S-phase fraction in relation to overall survival and disease free survival in transitional cell carcinoma of the bladder.
    Alderisio M; Cenci M; Valli C; Russo A; Bazan V; Dardanoni G; Cucciarre S; Carreca I; Macaluso MP; Tomasino RM; Vecchione A
    Anticancer Res; 1998; 18(6A):4225-30. PubMed ID: 9891471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and Predictive Value of O
    Zhang J; Zhu Y; Wang Y; Fu Q; Xie H; Liu Z; Fu H; Cao Y; Xu J; Dai B
    Ann Surg Oncol; 2018 Jan; 25(1):342-348. PubMed ID: 29116491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Flow cytometric analysis of the DNA content in the urinary bladder cancers treated by radical cystectomy and pre-operative irradiation].
    Toyota K; Nagamori S; Kashiwagi A; Nonomura K; Togashi M; Koyanagi T; Nojima T; Inoue K
    Nihon Hinyokika Gakkai Zasshi; 1992 Dec; 83(12):2050-7. PubMed ID: 1474714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The predictive value of flow cytometry and urinary cytology in the followup of patients with transitional cell carcinoma of the bladder.
    Giella JG; Ring K; Olsson CA; Karp FS; Benson MC
    J Urol; 1992 Aug; 148(2 Pt 1):293-6. PubMed ID: 1635121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Conservative treatment with chemotherapy and radiotherapy in bladder cancer invading the muscle: preliminary results of a prospective study].
    Zapatero A; Pinar B; Arellano R; López M; Marín A; Jiménez U; Pérez Torrubia A
    Arch Esp Urol; 1997 Jun; 50(5):448-54; discussion 454-6. PubMed ID: 9382586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An organ-sparing treatment using combined intra-arterial chemotherapy and radiotherapy for muscle-invading bladder carcinoma.
    Tsukamoto S; Ishikawa S; Tsutsumi M; Nakajima K; Sugahara S
    Scand J Urol Nephrol; 2002; 36(5):339-43. PubMed ID: 12487737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination transurethral resection, systemic chemotherapy, and pelvic radiotherapy for invasive (T2-T4) bladder cancer unsuitable for cystectomy: a phase I/II Southwestern Oncology Group study.
    Einstein AB; Wolf M; Halliday KR; Miller GJ; Hafermann M; Lowe BA; Meyers FJ; Leimert JT; Crawford ED
    Urology; 1996 May; 47(5):652-7. PubMed ID: 8650861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective study of DNA ploidy of transitional cell carcinoma of urinary bladder using flow cytometry.
    Pan ST; Chan LP; Yu KC; Chang MC; Ho WL
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1994 Jan; 10(1):22-7. PubMed ID: 8176764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downstaging and survival benefits of neoadjuvant radiotherapy before cystectomy for patients with invasive bladder carcinoma.
    Granfors T; Tomic R; Ljungberg B
    Scand J Urol Nephrol; 2009; 43(4):293-9. PubMed ID: 19363744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802.
    Tester W; Caplan R; Heaney J; Venner P; Whittington R; Byhardt R; True L; Shipley W
    J Clin Oncol; 1996 Jan; 14(1):119-26. PubMed ID: 8558186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer.
    Maarouf AM; Khalil S; Salem EA; ElAdl M; Nawar N; Zaiton F
    BJU Int; 2011 May; 107(10):1605-10. PubMed ID: 20825396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.